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ABSTRACT 
THE EFFECT OF SILENCING THE WILMS' TUMOR 1 GENE ON THE 
RADIATION SENSITIVITY OF GLIOBLASTOMA CELLS 
By Dana C. Chan 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2006. 
Advisor: William C. Broaddus, M.D., Ph.D. 
Associate Professor, Department of Neurosurgery 
Associate Professor, Department of Anatomy and Neurobiology 
Glioblastomas are among the most devastating of human cancers with a 
median survival of only 9-12 months. This type of brain tumor is incurable, 
largely due its remarkable proliferative capacity and resistance to current 
treatments. High levels of the Wilms' Tumor 1 (WTI) gene have been identified 
in glioblastomas, suggesting an oncogenic function. Moreover, known WT? 
target genes have been implicated in resistance to radiation. To determine the 
role of WT1 in radiation resistance, two glioblastoma cell lines expressing WT1 
were treated with siRNAs to si.lence this gene. Confirmation of WT1 knockdown 
was achieved through real-time PCR and Western blot. After treatment with 
siRNA, cells were irradiated, and cell survival was assessed using a luminescent 
ATP assay and clonogenic survival assay. We demonstrate that treatment with 
WT1 siRNA increased the radiation sensitivity in both cell lines. These findings 
suggest that WT1 functions to protect glioblastoma cells from radiation-induced 
death. 
CHAPTER I 
INTRODUCTION 
1 .I Brain Tumors 
1 .I .I Overview of Brain Tumors 
The term primary brain tumor refers to a cluster of abnormally growing 
cells that originate from normal cells in the central nervous system (CNS), 
including both intracranial tissue and meninges. It is thought that these tumors 
occur as a result of genetic mutations which allow these cells to grow rapidly and 
invade surrounding tissue. Although these tumors very rarely metastasize 
outside the CNS, they are able to evade normal regulatory growth mechanisms 
and can cause severe damage. Patients with brain tumors typically present with 
four main types of symptoms1, the first being partial or generalized seizures. 
Second, the bulk of the tumor results in raised intracranial pressure and leakage 
of the blood-tumor and blood-brain barrier, causing vasogenic edema. This 
increased pressure can result in symptoms of headaches, nausea, vomiting, 
drowsiness, and visual abnormalities. Third, neurological deficits manifest 
depending on the location of the tumor. Lastly, patients may have cognitive 
dysfunction that varies with tumor type and grade. While the cause of brain 
tumors has yet to be identified, it is known that genetic inheritance occurs 
infrequently. Environmental factors such as the use of cellular phones, diet, and 
tobacco intake are currently being investigated as potential neurocarcinogens, 
although none have demonstrated strong associations with brain tumor 
incidence2. 
Primary malignant and benign CNS tumors combined occur at a rate of 
14.8 cases per 100,000 person-years3; that is, for every 100,000 people in one 
year, 14.8 individuals will be diagnosed with a CNS tumor. Malignant brain 
tumors are among the deadliest of cancers and account for approximately 2% of 
all cancers in adults2. These tumors occur at a rate of 6.4 cases per 100,000 
person-years3 and affect more men than women. Gliomas are brain tumors that 
originate from glial cells which normally provide support and nutrients to neurons 
in the CNS; these include astrocytes and oligodendrocytes. Furthermore, 
gliomas constitute 40% of all CNS tumors and 78-86% of all malignant brain 
turn or^''^. Thus, the focus of this paper will be on gliomas, specifically 
glioblastoma multiforme (GBM), which acco~~nts for over half of gliomas. 
Unfortunately, many gliomas are incurable and patient survival is poor in 
comparison to other cancers; prognostic factors include age, histologic subtype, 
tumor grade, and presenting ~ ~ m ~ t o m s l ; ~ ; ~ .  In addition, the Karnofsky 
Performance Scale (0-1 00) rates patients' overall functioning ability; generally, a 
higher score indicates a better prognosis. 
The majority of gliomas are supratentorial; that is, they are commonly 
located in the frontal, temporal, parietal, and occipital lobes of the brainli2. As a 
result, patients present with symptoms such as motor or sensory deficits, 
hemianopsia, aphasia, or a combination of these1. In the United States, gliomas 
occur at a rate of 5.9 per 100,000 person-years3 and can be further divided into 
different categories. The World Health Organization (WHO) classification and 
grading system is the most widely used scheme to categorize gliomas and is 
based on the cell type the glioma was derived from. The three main types of 
gliomas are astrocytomas (of astrocytic origin), oligodendrogliomas (of 
oligodendrocytic origin), and mixed oligoastrocytomas which display features of 
both astrocytes and oligodendrocytes. Each of these types of gliomas can be 
distinguished by histological examination and biological markers. WHO grading 
is dependent on four main features: 1) nuclear atypia, 2) mitoses, 
3) microvascular proliferation, and 4) necrosis1. Astrocytomas are graded on a 
scale of I-IV in order of increasing malignancy; these include pilocytic 
astrocytomas (WHO grade I), diffuse astrocytomas (WHO grade II), anaplastic 
astrocytomas (WHO grade Ill), and glioblastoma multiforme (WHO grade IV). 
Oligodendrogliomas and mixed oligoastrocytomas only incorporate two grades: 
low grade (WHO grade II) and anaplastic (WHO grade Ill). It is believed that 
highly malignant (WHO grade IV) variants of the latter two types of tumor do 
occur, but are indistinguishable from the astrocytic variant of glioblastoma. 
WHO grades I and II are considered low grade gliomas; the median 
survival of these patients ranges from 12-1 28 months. These tumors mostly 
affect young adults and are commonly located in the frontal, temporal, and 
insular lobes of the brain. Up to 80% of patients with a grade I or II glioma 
present clinically with partial or generalized seizures1; fortunately, magnetic 
resonance imaging (MRI) allows clinicians to diagnose and manage this disease 
in its early stages more often. While grade I gliomas can be surgically curable if 
completely resected, the majority of low grade tumors are grade II and will 
eventually undergo malignant transformation. WHO grades Ill and IV gliomas 
are considered high grade or malignant; these include anaplastic astrocytoma 
(grade Ill) and glioblastoma (grade IV), which unfortunately are the most 
common types of glioma. The median survival of patients with anaplastic 
astrocytoma is 2-3 years, while the median survival of patients with glioblastoma 
is 9-12 months, despite the most aggressive treatment eff0t-t~';~;~. 
Of the 18,000 patients diagnosed each year with malignant primary brain 
tumors in the US, over half are diagnosed with a G B M ~ ; ~ ,  which occurs four times 
more frequently that anaplastic astrocytoma. Because GBMs are the most 
common malignant primary brain tumor in adults and are the most difficult to 
treat, the remainder of this paper will focus on this particular type of glioma. 
Glioblastomas are among the most devastating of human cancers; they are 
highly aggressive, invasive, and cause extensive neurological damage. The 
mean age at onset is about 53 years of age3, and regardless of maximum 
therapy, the majority of patients die within two years of diagnosis6. 
Glioblastoma is clinically characterized by rapid proliferation, diffuse 
invasion, angiogenesis, and cellular necrosis5. There are two pathways that lead 
to GBM';~;~;  a primary, or de novo GBM is typically observed in older patients 
without any evidence of prior clinical disease, whereas a secondary GBM usually 
presents in younger patients with evidence or prior history of a low grade 
astrocytoma. Within 5-1 0 years of initial diagnosis, the low grade astrocytoma 
usually transforms into a GBM, despite prior therapy. Although primary and 
secondary GBMs are clinically indistinguishable, each pathway most likely 
involves a different multistep pathogenesis with several genetic alterations. For 
example, primary GBMs exhibit amplification and overexpression of the 
epidermal growth factor receptor (EGFR)', loss of chromosome 10, amplification 
and overexpression of the murine double minute 2 (MDM2) gene, and deletion or 
mutation of the phosphatase and tensin homolog from chromosome 10 
(PTEN)' ;5;6;8 . In contrast, secondary GBMs are associated with inactivation of 
p53 and overexpression of platelet derived growth factor (PDGF) receptors and 
ligandsqi5-*. 
1 .I .2 Treatment 
At present, glioblastomas are unfortunately incurable and progresssion is 
inevitable despite treatment. Therefore, the goal of most treatments used today 
are to alleviate symptoms, increase survival time, and attempt to maintain the 
best possible quality of life for patients. The current standard therapy for GBM 
includes surgery where possible, radiation therapy, and adjuvant chemotherapy, 
each of which will be discussed in the following section. 
Surgical: Because recurrence occurs within 2-3cm of the original tumor in 
up to 80% of patients1, surgery aims to achieve maximum resection of the tumor 
to alleviate symptoms, as previously discussed, and to determine the histological 
type of the tumor, while preserving the greatest amount of normal tissue. 
Furthermore, since many tumors cause death through raised intracranial 
pressure, surgical resection may delay this occurrence. Several studies have 
shown that a more extensive resection is associated with longer survival for 
patients, and several advances have been made to maximize the extent of 
resection4. The first is image-guided surgery, which incorporates preoperative 
imaging data to target the location and extent of resection; these images, 
however, cannot account for movements of the brain during the operation and 
therefore cannot accurately detect residual tumor at the end of the procedure. 
lntraoperative imaging involving CT, ultrasound, and MRI can help correct for this 
and may improve accuracy, although these techniques are expensive and 
limited. Awake craniotomy is a third approach that is used to maximize the 
resection margin by monitoring the patient's neurological function while removing 
the tumor; this is done when the tumor is located in eloquent areas such as the 
motor strip and speech areas. Lastly, fluorescence-guided surgery can maximize 
the resection margin as well. A phase Ill randomized trial was recently 
completed by a group in Germany, who reported that the use of this technique 
allowed for a higher rate of complete resection in addition to a higher 6 month 
progression-free survival in comparison to the control groupg. In this procedure, 
patients are preoperatively injected with a compound that is taken up by glioma 
cells and converted into a fluorescing substance; this substance can then be 
visualized by an operating microscope that is modified to incorporate the 
appropriate illumination. 
Radiation therapy: Several studies have shown that radiation therapy 
significantly improves survival time'. As part of standard treatment for GBMs, 
adjuvant radiation therapy is given to a localized and clearly defined treatment 
field. It is generally administered in a fractionated fashion; that is, a 1.8-2Gy 
dose is administered repeatedly over a period of about 6 weeks to deliver a total 
radiation dose of 58-60Gy. Another form of radiation therapy is brachytherapy, in 
which a radiation source is implanted into the tumor bed at the time of resection 
to deliver a high dose to the resection margin with minimal exposure to distant 
sites. Although various sources have been investigated, the most commonly 
used radioactive substance is Iodine-125. While the addition of radiation therapy 
to surgery significantly increases average survival in these patients, long-term 
survival remains extremely rare because glioblastomas are relatively resistant to 
radiation. 
Medical: The role of adjuvant chemotherapy for the treatment of GBM is 
highly debatable. Over 30 years of clinical trials have investigated the efficacy 
and benefit of chemotherapy in the treatment of malignant gliomas. 
Unfortunately, the results have been rather disappointing. The most investigated 
agents are nitrosoureas, but their efficacy is quite controversial. While some 
studies report a significant increase in 18-month survival, other studies report 
that adjuvant chemotherapy with nitrosoureas have no effect on survival'. 
Lonardi, et al summarized past clinical trials that have investigated various 
compounds in adjuvant chemotherapy; the most significant increase in survival 
was seen in patients who were treated with both temozolomide and radiation 
therapy1'. This phase Ill randomized trial conducted by the European 
Organization for Research and Treatment of Cancer reported that patients newly 
diagnosed with GBM demonstrated significantly increased 2-year survival when 
treated with temozolomide and radiation therapy versus radiation therapy 
alone1'; median progression-free survival increased from 5 to 6.9 months, while 
median overall survival increased from 12.1 to 14.6 months. Another clinical trial 
demonstrated the promise of using carmustine (a nitrosourea) wafers implanted 
into the tumor bed at the time of resection; unfortunately, the wafers became 
unavailable and completion of the study could not be ac~om~l ished '~ .  Despite 
these encouraging advancements, the fact remains that long-term outcome is still 
relatively unaffected and resistance to chemotherapy is very common. 
Genetic and Molecular: Because glioblastomas are resistant to both 
radiation therapy and chemotherapy, the biology of these tumors is becoming 
increasingly important. An understanding of the mechanisms by which these 
tumors proliferate or evade current treatment strategies is essential to either 
block their growth or render them susceptible to adjuvant therapy. Thus, newer 
strategies are under investigation, which aim to target ,the molecular and genetic 
features of GBMs that aid their growth. For example, studies are being 
conducted to assess the effects of inhibiting 06-methylguanine-DNA- 
methyltransferase, the enzyme responsible for resistance to chemotherapy with 
DNA alkylating agents such as carmustine and temozolomide. Additional studies 
are looking at the inhibition of signaling pathways responsible for progression 
through the cell cycle, stimulation of apoptosis, and inhibition of angiogenesis to 
block the blood supply source to the tumor. 
More specifically, small molecule inhibitors that block tyrosine kinase 
receptors, such as EGFR and PDGFR, are being tested for their efficacy in 
improving patient ~ u r v i v a l ~ ; ~ ~ ;  no significant results have currently been reported. 
It has been shown that an overactive EGFR pathway is associated with 
resistance to radiation therapy14-16, so the use of these inhibitors in conjunction 
with radiation therapy or chemotherapy may increase the effectiveness of current 
treatments. In fact, recent clinical trials have shown that combined use of the 
EGFR antibody and radiation therapy improved tumor control and survival in 
17;18 patients with head and neck cancer versus radiation therapy alone . In 
addition, the EGFR antibody in combination with both radiation therapy and 
temozolomide to treat glioblastomas is currently in a Phase 1/11 trial in ~ e r m a n ~ ' ~  
More downstream targets are also under investigation, such as the P13KIAKT 
pathway which is activated by EGFR and PDGFR. The P13WAKT pathway has 
recently been associated with greater resistance to radiation therapy in 
gliomas20. The PTEN gene product normally inhibits this pathway, but as 
previously mentioned, PTEN is either deleted or mutated in 40-50% of GBMs. 
Thus, current clinical trials are also studying the efficacy of inhibiting the 
P13WAKT pathway6. Hence, a better understanding of the molecular 
characteristics of glioblastomas is very important to develop advancements in 
therapeutic regimens. It is to be hoped that these targeted therapies in 
combination with current standard care will improve patient management and 
may eventually lead to a cure for this deadly disease. 
1 .I .3 Molecular Biology of Brain Tumors Pertaining to Radiation 
One of the main reasons radiation therapy cannot cure glioblastomas is 
because it is impossible to deliver a high enough dose to the treatment field that 
will eradicate all clonogenic tumor cells without significantly affecting the 
surrounding normal tissue. It is currently believed that factors which affect 
radiation sensitivity include distribution of cells throughout the cell cycle, the 
number of dividing cells, the number of cells with clonogenic capacity to 
reestablish uncontrolled growth, the ability of cells to repair radiation-induced 
DNA damage, and the ability of cells to undergo programmed cell death when 
necessary. These factors will be explored in the following section with a 
particular emphasis on how tumor cells are thought to evade destruction. 
Cell Cycle: The cell cycle is a determined set of events that culminates in 
the division of one cell into two identical daughter cells. There are 4 phases of 
the cell cycle: 1) the G I  phase is a period of growth 2) DNA synthesis occurs in 
the S phase 3) the G2 phase is when cells continue to grow and prepare for 
cellular division 4) the M phase is the period in which cells undergo mitosis. 
Cells can also exit the G I  phase and enter GO, the quiescent or resting phase; 
non-dividing cells remain in the GO phase and do not progress through other 
phases of the cell cycle. Between each phase, there are checkpoints that serve 
to regulate proper progression into the next phase to ensure the production of 
two healthy daughter cells. 
The G I  checkpoint ensures that cells are the proper size and have 
accurate copies of DNA before they can enter the S phase; tumor cells with a 
defective G I  checkpoint are more resistant to radiation compared to normal 
cells2'. The S phase checkpoint ensures that DNA has been replicated; radiation 
inhibits both the initiation and elongation stages of DNA replication2'. The G2 
checkpoint also ensures that DNA has been replicated accurately before cells 
are allowed to enter the mitosis phase. The DNA damage checkpoint detects 
damaged DNA and causes cells to arrest in GI ,  slow down progression in S, and 
arrest in G2; it also induces the transcription of repair genes to mend the 
damaged DNA~'. Progression from G I  to S and G2 to M are mediated by a 
group of enzymes called cyclin-dependent kinases (CDKs); these enzymes are 
activated by cyclins, whose expression is highly regulated within the cell. 
Radiation induces nuclear DNA damage, resulting in single- and double- 
strand DNA b reak~~ l - ' ~ .  This causes cells to arrest in G I ,  S, and more 
commonly, in the G2 Cells in the M phase or in the G I  to S phase 
transition are reported to be more sensitive to radiationz4. When a cell sustains 
damage due to ionizing radiation, it will enter one (or possibly both) of two 
pathways: survival and repair, or apoptosis. Commitment to either pathway 
depends on the extent of damage, as well as genetic and environmental factors. 
Minor or moderate DNA damage will induce cell cycle arrest, followed by repair 
and resumption of proliferation. Major DNA damage will also induce cell cycle 
arrest and an attempt to repair damages; if repair is successful, the cell will 
resume proliferation, but if not, the cell will undergo delayed apoptosis. 
Irreparable DNA damage will cause the cell to undergo early apoptosis. 
Repair mechanisms: When a cell incurs DNA damage, particularly a 
double-strand break, the entire genome becomes compromised. If the proper 
repairs are not made, all the genes distal to the break will be lost as the cell 
divides, which can lead to cell death. Furthermore, if the repair is not accurate 
and cells continue to proliferate, genetic mutations can be introduced which may 
cause severe damage to the organ and its surrounding tissue. DNA damage 
recognition and repair pathways have therefore evolved to prevent such 
consequences. These mechanisms are responsible for ensuring that damaged 
cells arrest growth at any of the cell cycle checkpoints until repair is efficiently 
and accurately completed. 
It is currently believed that at least three pathways exist to repair double- 
strand breaksz6. The first pathway is based on homologous recombination with 
an intact copy of the damaged sequence being either the homologous 
chromosome or a sister chromatidz7. This strand serves as a template for 
synthesis of a new complement strand, and is highly accurate in most casesz8. 
The other two pathways incorporate nonhomologous end-joining (N H EJ), in 
which there is no intact homologous copy to serve as a template; each of these 
pathways is mediated by a different complex of proteins. The predominant NHEJ 
pathway is probably the Ku-dependent pathway which joins the ends of partially 
complementary 3' overhangs, followed by polymerization of missing 
sequencesz6. The other NHEJ pathway involves the separation of ends by a 
helicase or resection by an exonuclease to expose short homologous DNA 
sequences called microhomologies. These microhomologies then anneal and 
the resulting double-strand DNA is trimmed and ligated to form the final 
product26. NHEJ is the most common double-strand break repair mechanism in 
mammalian cells; unfortunately, the lack of an intact copy also makes it more 
error-prone26. While defects in double-strand break repair machinery can 
promote the likelihood of malignant transformation, it can also be used in 
targeted therapies for cancers; if repair of the DNA can somehow be prevented 
altogether, the cell will be forced to undergo apoptosis, thus enhancing the 
effects of radiation and/or chemotherapy. 
Apoptosis: Current knowledge in cell biology suggests that there are 3 
mechanisms of cell death; the first is necrosis, a disordered event that results in 
inflammation of the surrounding tissue. The second is autophagy, in which 
cellular components are sequestered and delivered to the lysosome for 
degradation. The third form is apoptosis, a highly ordered and evolutionarily 
conserved mechanism, in which cells undergo programmed cell death when 
damages incurred by the cell are irreparable. Apoptosis is the major mechanism 
by which radiation kills ~ e l l s ~ ~ ; ~ ' ;  in respects to radiation, two types of apoptosis 
have recently been termed. In premitotic apoptosis, cells commit suicide before 
reaching the mitotic phase; this type of apoptosis is usually induced by high dose 
radiation, mainly occurs in the S phase, and involves rapid or early apoptosis30. 
In postmitotic apoptosis, cells commit suicide after having gone through one or a 
few cycles of mitosis; it is usually induced by low dose radiation, occurs mostly in 
the G I  phase, and involves delayed a p o p t o ~ i s ~ ~ .  Postmitotic apoptosis is also 
characterized by the loss of clonogenic cell survival, and death most likely results 
from reaching a critical level of genomic instability. 
Apoptotic cells generally display distinct morphological and biochemical 
features such as DNA fragmentation, chromatin condensation, membrane 
blebbing, and cytoplasm shrinkage. The culmination of these events results in 
the formation of apoptotic bodies that are phagocytosed by the appropriate cells 
to prevent inflammation and damage to surrounding tissue2'. Apoptotic events 
are mediated by a family of cysteine proteases called caspases that are 
synthesized as procaspases in the cell; an apoptotic signal will trigger the 
conversion of these zymogens into active caspases that execute cellular suicide. 
There are two major apoptotic pathways 29;31-33 , one of which is mitochondria- 
initiated and occurs through caspase-931;34;35. DNA damage triggers the release 
of cytochrome c from the mitochondria; this molecule then interacts with Apafl to 
form a complex that binds to and activates caspase-9. Caspase-9 then activates 
downstream targets to execute cell death. The release of cytochrome c is 
regulated by anti-apoptotic and pro-apoptotic members of the Bcl-2 family of 
proteins. The other pathway is death-receptor-mediated and requires caspase- 
831 ;34;35 
. A ligand such as Fas or Tumor Necrosis Factor a (TNFa) binds to the 
death receptor, inducing a conformational change that recruits another molecule, 
Fas Associated Death Domain (FADD). FADD then binds to and cleaves 
procaspase-8 into an active enzyme that will activate downstream targets to 
achieve cell death. 
The p53 protein is a major mediator of apoptosis, although programmed 
cell death can occur either in a p53-dependent or p53-independent fashion. 
Recent evidence suggests that radiation induces activation of caspase-8 in 
glioma cells lacking functional p53, mediating a p53-independent apoptosis 
pathway3'. Apoptosis is also mediated by the molecule ~ e r a m i d e ~ ~ ; ~ ~ ;  exposure 
to radiation induces the enzyme sphingomyelinase to hydrolyze plasma 
membrane-derived sphingomyelin, producing ceramide. This will also lead to 
apoptosis, although the exact pathway has yet to be elucidated. 
Glioblastoma and radiation: Despite all these complex intrinsic 
mechanisms, glioblastoma cells still remain resistant to radiation therapy. P53 
does mediate growth arrest in radiated tumor cells; however, small populations of 
clonogenic cells are able to re-establish uncontrolled growth and lead to tumor 
r e c ~ r r e n c e ~ ~ ; ~ ' .  Not surprisingly, molecules that regulate apoptosis or cell cycle 
progression and proliferation are thought to play a role in radiation sensitivity. 
For example, the molecule survivin has been proposed as a key factor in 
protecting glioblastoma cells from radiation 29;31;37;38. , this molecule is a member of 
the family of inhibitor of apoptosis proteins and is involved in modulation of 
apoptosis as well as regulation of cell gro~th39;40. Survivin suppresses caspase- 
mediated apoptosis by directly binding to and inhi biting caspase-g40. 
Furthermore, increased levels of survivin have been correlated with a worse 
prognosis and decreased survival times in patients with glioblastoma, in addition 
to reduced apoptotic ability of the tumors4'. Other studies demonstrate that 
survivin plays a role in cell division to control both microtubule stability and 
assembly of normal mitotic spindle, which may facilitate evasion from cell cycle 
 checkpoint^^^. 
Bcl-2 family members have also been shown to play a role in radiation 
resistance in glioblastoma. Glioma cell lines with lower BAX expression (a pro- 
apoptotic member) were more resistant to radiation than those with higher 
expression; conversely, glioma cell lines with increased Bcl-X expression (an 
anti-apoptotic member) were also more resistant to radiation than those with 
lower exp re~s ion~~ .  Other groups are investigating the role of vascular 
endothelial growth factor (VEGF), which has been demonstrated to increase after 
radiation in glioblastoma cell linesM; this may implicate a role for angiogenesis in 
resistance to radiation. And, as previously mentioned, various studies have 
demonstrated that overexpression of EGFR or overly active EGFR pathways are 
14-16 also associated with radiation resistance . 
1.2 Wilms' Tumor 1 
1.2.1 Overview and Characterization 
Wilms' tumor, also commonly known as nephroblastoma, is a malignant 
pediatric kidney tumor that was first described by Max Wilms in 1899. 1 in 
10,000 children are affected by this tumor, and it accounts for 7.5% of all 
childhood tumors45. The observation of karyotype abnormalities in predisposed 
children and molecular genetic examinations of Wilms' tumor specimens led to 
the identification of the Wilms' tumor 1 gene (WT1)46, located at chromosome 
locus 11 p13; it spans about 50kbp, contains 10 exons, and produces mRNAs of 
47;48 about 3kbp . Originally classified as a tumor suppressor, extensive research 
has demonstrated that this protein is highly complex with a number of possible 
functions and is associated with over 20 target genes, a few of which will be 
discussed further. Numerous studies have implicated that the WT1 protein 
functions in a variety of cellular processes including proliferation, differentiation, 
45;49 and apoptosis . 
The N-terminus is rich in proline and glutamine, suggesting functions as a 
transcription factor, while the C terminus contains 4 Cys2-His2 zinc fingers47. 
The zinc fingers are thought to be a possible DNA binding domain since it shares 
remarkable homology with the early growth response 1 (EGR-1) transcription 
factor. Exons 5 and 9 of the message are alternatively spliced, which result in 4 
different i s o f ~ r m s ~ ~ ; ~ ~ .  Exon 5 consists of a stretch of 17 amino acids and is 
located between the N-terminus and the zinc fingers. Exon 9 incorporates the 
three amino acids, lysine, threonine, and serine (KTS) between the third and 
fourth zinc fingers. The (+I+) isoform includes both exons, while the (-I-) isoform 
lacks both exons. The (-I+) isoform lacks exon 5, but includes exon 9, and 
conversely the (+I-) isoform includes exon 5, but lacks exon 9. WT1 (+I+) is the 
most prevalent isoform in humans and the (-I-) isoform is the least common50. 
The WT1 proteins have molecular masses of 52 and 54kD; the (-I-) isoform is 
52kD, and the (+I+) is 5 4 k ~ ~ ' .  Additional mRNA editing produces a total of eight 
different mRNA isoforms5*, while differences in translation initiation produce 24 
different protein i s ~ f o r m s ~ ~ ; ~ ~ .  Thus begins the enormous complexity of this 
molecule, suggesting a large potential of different functions. 
1.2.2 Potential Functions 
Regulator of transcription: A number of studies have been conducted 
to study the role of WT1 as a possible transcription factor. Results have shown 
that WT1 can either activate or repress a number of genes, but that its 
transcription-regulating activity depends on the choice of cell system, expression 
vector, or the topology of the reporter construct49. For example, it has been 
demonstrated that the WT1 (-I+) isoform functions to suppress the p-153 PDGF 
promoter, whereas it activates the shorter p-60 PDGF promoter55. It is currently 
unknown what role the splice variants play in regulation of transcription, but 
recent data suggest that the splice variants may differentially regulate the same 
target genes. The WT1 proteins that both include exon 9 (+KTS) and lack exon 9 
(-KTS) have been shown to bind overlapping DNA sequences in the promoters 
of the IGF-II gene56, as well as the genes encoding the PDGF-A chain55, Wilms' 
tumor and ~ ~ x - 2 ~ ~ .  Furthermore, it has also been observed .that the WT1 
(+I+) isoform suppresses transcription of a modified PDGF-A promoter construct 
while the WT1 (-I+) isoform activates its tran~cript ion~~. 
Post-transcriptional regulation: There is also evidence to suggest that 
WT1 is involved in the post-transcriptional processing of RNA. An evolutionarily 
conserved RNA recognition motif in the N-terminus of all WT1 isoforms has been 
identified5'; Caricasole et a1 showed that the zinc fingers of both the (+KTS) and 
(-KTS) proteins are involved in binding to exon 2 of the IGF-II transcript6'. In 
addition, Larsson et a1 used nuclear staining to demonstrate that the (+KTS) 
proteins localize in the nucleus in a "speckled" pattern similar to that of clusters of 
interchromatin granules that contain components of spliceosomes6'. 
Furthermore, Davies et a1 showed that WT1 not only associates directly with the 
splicing protein U2AF65, but that it can also incorporate into spliceosomes in an 
in vitro splicing assay62; these data suggest a potential role of WT1 in splicing 
events. Thus, WT1 can exert powerful effects in its ability to regulate gene 
expression at various different levels. 
Influence on apoptosis: WT1 has been shown to be capable of both 
inducing and inhibiting apoptosis. For example, expression of the 4 splice 
variants have been revealed to induce apoptosis in 2 osteosarcoma cell lines63, 
while the (-KTS) isoform has been demonstrated to induce apoptosis in 2 
hepatoma cell lines64. In contrast, WT1 can bind to the p53 protein through its 
zinc and effectively suppress p53-mediated apoptosis without 
affecting p53-mediated cell cycle arrests6. Moreover, WT1 has been shown to 
transcriptionally activate the Bcl-2 gene which encodes an anti-apoptotic 
chemotherapy agents that exert their effects by inducing apoptosis 
are rendered ineffective in these cells expressing WT1 and consequent 
upregulation of BCI-268. While this paradoxical effect may seem baffling, such 
results have been used to support the concept that the activity of WT1 depends 
on cell type, expression vector, and topology of the reporter construct. 
Tumor suppressor or oncogene: As previously mentioned, WT1 was 
originally classified as a tumor suppressor; it is now currently debated whether 
WT1 acts as a tumor suppressor or as an oncogene. Unlike most tumor 
suppressors, WT1 is not ubiquitously expressed throughout the body, nor is it 
commonly mutated in various cancers. In fact, a homozygous WT1 mutation is 
found in only 5-10% of Wilms' tumors". Furthermore, WT1 has been found to be 
overexpressed in a myriad of tumors including lung cancers, colorectal 
adenocarcinoma, thyroid cancers, pancreatic ductal adenocarcinoma, leukemias, 
70-77 and breast cancer , to name a few. Additionally, high levels of WT1 have 
been correlated with a worse prognosis in patients with breast cancer and acute 
72;78 leukemia . These data, in accordance with its ability to suppress apoptosis, 
argue that WT1 functions more as an oncogene than as a tumor suppressor. 
1.2.3 Role in Brain Tumor Biology 
In addition to the cancers mentioned above, the expression of WT1 has 
also been demonstrated in gliomas; using RT-PCR, Dennis et a1 identified 215 
low grade gliomas, 217 anaplastic astrocytomas, and 719 glioblastomas79 to 
express WT1 with no mutation of the zinc fingers. Another group used 
immunohistochemical staining to demonstrate that 48/51 glioblastoma samples 
were positive for WT1 protein, and that high levels of WT1 mRNA were also 
expressed in the GBM samplesg0. Moreover, WT1 was found to be expressed in 
516 low grade astrocytic tumors and 18/18 high grade gliomas, and WT1 
expression in the high grade gliomas was significantly elevated in comparison to 
expression in low grade specimens; WT1 protein was not detected in normal glial 
cells contained in these tumor specimensg'. This same group also tested for 
mutations in the glioblastoma samples, none of which were found. Additionally, 
this group treated glioblastoma cell lines with antisense WT1 oligomers, which 
significantly inhibited their growth in comparison to the control group treated with 
random oligomers, although confirmation of WT1 knockdown was not made. Our 
laboratory has also identified WT1 mRNA expression in 519 GBM cell lines, 1311 6 
low grade gliomas, and 44150 GBM specimens. These data suggest that WT1 
acts as an oncogene in GBM, although its exact role is still unknown. 
1.2.4 WTI and Radiation Sensitivity 
Among the multitude of WT1 target genes is EGFR. While it activates 
EGFR in the PC12 rat pheochromocytoma cell line82, it also represses EGFR in 
osteosarcoma cell lines to induce a p o p t ~ s i s ~ ~ ;  this paradox, however, may be 
attributed to cell-type dependent functions. Nonetheless, since EGFR is found to 
be overexpressed in glioblastoma7 and overexpression of EGFR has been 
associated with the resistance of glioblastoma cells to radiat i~n'~- '~,  it is possible 
that WT1 may be responsible for this resistance due to its regulatory functions on 
EGFR. Moreover, the P13WAKT pathway, activated by EGFR and PDGFR, has 
also been associated with increased resistance to radiation2', and both EGFR 
and PDGFR have been shown to be regulated by W T ~ ~ ~ ; ~ ~ ; ~ ~ ;  these data further 
signify a potential role of WT1 in radiation resistance. Additionally, the Bcl-2 
family members have been associated with radiation resistance in G B M S ~ ~ ;  since 
WT1 regulates B C I - ~ ~ ~ ; ~ ~ ,  WT1 may be the upstream signal that is aiding 
glioblastoma cells to evade destruction. Lastly, WT1 has been shown to bind 
~ 5 3 ~ ~ ; ~ ~  and to suppress p53-mediated a p o p t ~ s i s ~ ~ ,  which may also account for 
the observed resistance. Whatever the case, little is known about how 
glioblastoma cells evade eradication by radiation, and WT1 may provide clues 
that will help solve this mystery. 
1.3 Hypothesis and Specific Aims 
There is convincing evidence that WT1 plays a role in glioblastoma; 
because the target genes of WT1 have been implicated as responsible for 
radiation resistance in glioblastoma cells, we hypothesized that WT1 functions to 
promote cell survival, despite severe radiation-induced damage. 
We aimed to characterize the effects of radiation on glioblastoma cell lines 
expressing WTI, and to determine the effect of silencing WT1 on radiation 
sensitivity. We used siRNAs to knockdown WT1 in 2 glioblastoma cell lines and 
confirmed knockdown by real-time polymerase chain reaction (PCR) and 
Western blot. We then irradiated these cells with a Cesium-137 source and 
determined cell proliferation by an ATP cell viability assay and the clonogenic cell 
survival assay. We hypothesized that silencing WT1 with RNA interference 
would enhance the radiation sensitivity of glioblastoma cells. 
CHAPTER 2 
MATERIALS AND METHODS 
2.1 Cell Culture 
Human glioblastoma derived cell lines (Ln18 and T98G) were obtained 
from American Type Culture Collection and cultured in I x  Dulbecco's Modified 
Eagle Medium (Invitrogen) supplemented with 10% heat-inactivated Fetal Bovine 
Serum (FBS from Biomeda), 1 % L-glutamine (Invitrogen), 1 % penicillin1 
streptomycin (Invitrogen), and 1 % non-essential amino acids (Invitrogen). Both 
cell lines were maintained in a humidified incubator at 37°C with a 5% carbon 
dioxide concentration. 
2.2 siRNA Transfection 
Cells were plated at a density of 250,000 cells in 2mL complete media per 
well in 6 well plates. The following day, each well was washed with 2mL I x  Opti- 
MEM Reduced Serum Medium (Invitrogen) supplemented with 1% penicillin1 
streptomycin. 800uL of Opti-MEM was then added to each well, and each well 
was transfected with a final concentration of 100nM siRNA using Oligofectamine 
Reagent (Invitrogen). For each well, 4.7uL of Oligofectamine Reagent was 
combined with 12.8uL of Opti-MEM and incubated at room temperature for 10 
minutes. In a separate tube, 100nM siRNA (Dharmacon) was added to 204uL 
Opti-MEM; the OligofectamineIOpti-MEM solution was then added to the 
siRNAlOpti-MEM solution, mixed, and incubated at room temperature for 20 
minutes. 200uL of the final solution was then added to each well and incubated 
at 37°C for 4 hours. 500uL of a 3x FBSIOpti-MEM solution was then added to 
each well. 
siRNAs targeting WT1 consisted of a pool of 4 siRNAs synthesized by 
Dharmacon; the sequences are as follows: 
I ) sense: 5'-CUACAGCAGUGACAAUU UAU U-3' 
antisense: 5'-UAAAUUGUCACUGCUGUACUU-3' 
2) sense: 5'-GGAAUCAGAUGAACU UAGGU U-3' 
antisense: 5'-CCUAAGUUCAUCUGAUUCCUU-3' 
3 )  sense: 5'-GGACUGUGAACGAAGGUUUUU-3' 
antisense: 5'-AAACCUUCGU UCACAGUCCU U-3' 
4) sense: 5'-UACCCAGGCUGCAAUAAGAUU-3' 
antisense: 5'-UCUUAUUGCAGCCUGGGUAUU-3' 
siCONTROL Non-Targeting Pool (Dharmacon) was used as a control and will be 
referred to as siscramble; this pool consists of 4 non-targeting siRNAs. 24 hours 
after transfection, cells were washed with I x  PBS and detached with 1 mL of I x  
Trypsin-EDTA (Invitrogen), neutralized with 4mL complete media, and spun at 
1000rpm for 5 minutes at 24°C. Cells were then resuspended in fresh media, 
counted via Trypan Blue, and re-plated into corresponding plates for the 
clonogenic cell survival assay and the luminescent cell viability assay as 
described below. 
2.3 Irradiation 
48 hours after siRNA transfection, cells were treated with y-irradiation 
using a Cesium-source Mark I Irradiator (Cs-137, 4.149Gylmin) at indicated 
doses. This time point was chosen to allow cells to recover from the possible 
stress sustained from re-plating. 
2.4 Clonogenic Cell Survival Assay 
Following siRNA transfection as described above, Ln 18 cells were 
harvested and re-plated into 6 well plates at a density of 500 cells in 3mL of 
complete media per well; each treatment group was plated in triplicate. Plates 
were then irradiated 48 hours after transfection at indicated doses; 8 days after 
irradiation, the media was removed and each well was washed with l x  room 
temperature PBS. 600uL of methanol was then added to each well to fix the 
cells and plates were incubated at room temperature for 30 minutes. The 
methanol was then removed and 1 mL of Giemsa Stain, diluted 1 :2 in nanopure 
water, was added to each well and incubated for 1 hour. The Giemsa Stain was 
then removed and each well was washed 3 times with nanopure water. Colonies 
consisting 2 50 cells were counted. 
2.5 Luminescent Cell Viability Assay 
Experiments were performed using a semi-automated ATP assay in 96 
well plates to determine the number of viable cells after treatment. This assay 
quantifies the amount of ATP present, which is an indicator of metabolically 
active cells. The luciferase reaction is used to generate a luminescent signal that 
is proportional to the amount of ATP present, which is proportional to the number 
of viable cells in culture. In addition to citing a number of studies that support the 
use of ATP bioluminescence to measure viable cell number, Promega has also 
validated this technique by demonstrating a linear relationship between the 
number of cells in culture and the luminescence measured with their product. 
Similar studies with this assay in our laboratory, including with the cell lines 
utilized for these studies, have confirmed an excellent linear correlation between 
relative luminescence units (RLU) produced and viable cell number, as quantified 
by Trypan blue exclusion (data not shown). 
Following siRNA transfection, both Ln18 and T98 cells were harvested 
and re-plated into white 96 well plates with clear bottoms at a density of 1000 
cells in 1 OOuL of complete media per well; each treatment group was plated in 10 
replicates. Plates were then irradiated 48 hours after siRNA transfection at 
indicated doses; 5 days after irradiation, CellTiter-Glo@ Luminescent Cell Viability 
Assay (Promega) was performed according to the protocol supplied by the 
manufacturer. After the buffer, substrate, and plates were equilibrated to room 
temperature, the buffer was added to the substrate and inverted several times to 
ensure thorough mixing. 100uL of this solution was added to each well, and the 
plate was placed on an orbital shaker for 2 minutes to induce cell lysis. The plate 
was then incubated at room temperature for 10 minutes to allow stabilization of 
the signal, and subsequently read in the Lumi Star (BMG) Luminometer. 
Replicates were averaged and plotted as either Average RLU or as percent 
survival. Percent survival was calculated by taking each irradiated replicate of a 
treatment group and dividing it by the average of the corresponding non- 
irradiated treatment group; the average of these values was plotted. 
2.6 RNA Isolation and Real-time PCR 
RNA was extracted from both cell lines using TRlzol Reagent (Invitrogen) 
according to the manufacturer's protocol. Cells were plated in 6 well plates at a 
density of 250,000 cells in 2mL of complete media per well. Each treatment 
group was transfected in triplicate the following day with Oligofectamine only or 
siRNA (in Oligofectamine reagent). 48 hours after transfection, the media was 
removed; the wells were washed with room temperature I x  PBS, and 1 mL of 
TRizol reagent was added directly to each well and incubated for 5 minutes at 
room temperature. The TRlzol/cell solution was then transferred to a 1.5mL 
RNase-free Eppendorf tube and 200uL of chloroform was added to each tube. 
The tubes were shaken vigorously for 15 seconds, incubated at room 
temperature for 3 minutes and then spun at 12,000g for 15 minutes at 4°C. The 
aqueous phase containing the RNA was then removed and transferred into a 
new tube. 500uL isopropyl alcohol was added to each tube, and the tubes were 
inverted several times to mix the solution and incubated at room temperature for 
10 minutes. The tubes were then spun at 12,000g for 10 minutes at 4°C. The 
supernatant was discarded, and 1 mL of 75% ethanol was added to each tube. 
The tubes were vortexed briefly and subsequently spun at 7500g for 5 minutes at 
4°C. The supernatant was again discarded, and the pellets were air-dried to 
allow evaporation of the ethanol. 30uL of DEPC water was then added to each 
tube and incubated in a 55°C water bath for 10 minutes to resuspend the pellet. 
RNA was quantified by a spectrophotometer, by measuring the 
absorbance of the sample at the 260nm wavelength. Prior to real-time PCR, the 
RNA samples were treated with DNase (Promega). In an RNase-free Eppendorf 
tube, 1 ug of RNA was combined with I uL RQI 1 Ox reaction buffer and I uL of 
RQI RNase-free DNase. Samples were then incubated in a 37°C water bath for 
30 minutes. I uL of Stop Solution (20mM EGTA) was then added to each 
sample, and the samples were incubated in a 65°C water bath for 10 minutes. 
Real-time PCR was performed using the ABI Prism@ 7900 Sequence 
Detection System in the Molecular Core of the Virginia Commonwealth 
University-Massey Cancer Center Nucleic Acids Research Facilities. 10uL 
reactions were prepared in 384 well plates from TaqMan@ One Step RT-PCR 
Master Mix Reagents Kit (ABI), RNase-free water, 0.9uM each of the forward and 
reverse primers, 0.3uM of the TaqMan probe, and 20ng of RNA. All samples 
were tested in triplicate under the following cycling conditions: 48°C 130min; 
95°C / I  Omin; and 40 cycles of 95°C / I  5sec and 60°C / I  min. The cycle threshold 
was determined to provide the optimal standard curve values (0.98 to 1.0). The 
probes and primers were designed using the Primer Express@ 2.0 version. 
Probes were labeled in the 5'end with FAM (6-carboxyfluoresceine) and in the 
3'end with TAMRA (6-carboxytetramethylrhodamine). Ribosomal RNA (1 8s 
rRNA) from the Pre-developed TaqMan@ Assay Reagents (ABI) was used as an 
endogenous control. Primers and probe sequences for WT1 are as follows: 
Forward Primer: 5'-AGGACTGTGAACGAAGGTTTTCTC-3' 
Reverse Primer: 5'-GACAAGTTTTACACTGGAATGGTTTC-3' 
Probe: 5'-CACCTGTATGTCTCCTTTGGTGTCTTTTGAGCT-3' 
2.7 Protein Extraction and Western Blotting 
Cells were plated at a density of 250,000 cells in 2mL complete media per 
well in 6 well plates and allowed to attach overnight. Cell were then transfected 
in replicates of 6 the following day as described above; at indicated times 
following siRNA transfection, the 6 replicates were combined into one tube and 
protein was extracted using SDS buffer (50mM Tris-CI, 1 % SDS, 10% glycerol) 
supplemented with protease inhibitors. Protein concentrations were determined 
using the BioRad DC Protein Assay Kit. 100ug of protein was loaded into a 10% 
Bis-Tris gel and separated by SDS-PAGE. The protein was then transferred onto 
a nitrocellulose membrane, and the membrane was blocked with a 5% nonfat 
milk solution. Blots were then incubated with mouse anti-WT1 monoclonal 
antibody (Dako), diluted 1 :200, and washed in Tris buffered saline containing 
0.05% Tween-20 before and after incubation with anti-mouse secondary antibody 
conjugated to horseradish peroxidase, diluted 1 :I 000. Blots were then 
developed using the ECL Western Blotting Detection Reagents (Amersham). 
Rabbit anti-cyclophilin A monoclonal antibody (Upstate) was used to control for 
protein loading. 
Protein bands were quantified by densitometry using the Scanning Imager 
PDSl and ImageQuant software. The relative optical density (ROD) of each WT1 
protein band was measured and divided by the ROD of the corresponding 
cyclophilin A band. Total protein was reported as the sum of the ROD values of 
the two isoforms. 
2.8 Statistical Analysis 
An Analysis of Variance (ANOVA) followed by Tukey's HSD Post Hoc test 
was performed to determine differences between the four treatment groups 
(untreated, Oligofectamine control, siScramble, siWT1). A separate ANOVA 
value is reported for each of the three groups analyzed (control cells, irradiated 
cells, percent survival); this analysis was performed on all experiments requiring 
comparisons of more than two groups. Analysis of data comparing only two 
groups was performed using Student's t-Test. 
CHAPTER 3 
RESULTS 
3.1 Characterization of Irradiation Effects 
To determine the effects of irradiation on the glioblastoma cell lines, Ln18 
and T98, we performed an irradiation (IR) dose response using the luminescent 
cell viability assay based on ATP content (Figure l a ,  I b) and the cell clonogenic 
survival assay (Figure Ic). We determined the ED50 to be 5Gy for Ln18 cells 
and 7Gy for T98 cells using the luminescent cell viability assay, and 2Gy for Ln18 
cells using the clonogenic cell survival assay. These doses were then used to 
study the effects of WT1 on the radiation sensitivity of these cell lines. 
Additionally, time courses were performed to determine the optimal number of 
days after irradiation to perform the luminescent cell viability assay (Figure 2a - 
2d). Percent survival for each time point was calculated by dividing the relative 
luminescence units (RLU) of each irradiated replicate by the average RLU of 
non-irradiated controls; each time point had its own control. Following radiation 
exposure, cell viability decreased to a minimum value at 5 days, after which 
viability progressively increased, due to recovery and re-growth of the cell 
population. Thus, the optimal time to monitor cell viability appeared to be 5 days 
post irradiation for both cell lines. 
Figure 1. Irradiation Dose Response: Ln18 or T98 cells were plated into 96 
well plates (1 000 cells per well) and incubated for 24 hours prior to radiation 
exposure. After carrying out radiation exposure, the plates were incubated for 5 
days, following which they were subjected to the luminescent cell viability assay 
for ATP content. The ED50 was determined to be 5Gy in Ln18 cells ( I  a) and 7Gy 
in T98 cells ( I  b). Ln18 cells were also assessed for clonogenic survival; cells 
were plated in 6 well plates (500 cells per well) and incubated for 24 hours prior 
to radiation exposure. After incubation for 8 days post irradiation, cells were 
analyzed. Using the clonogenic cell survival assay, the ED50 was determined to 
be 2Gy in Ln18 cells ( I  c). Results shown for the luminescent cell viability assay 
are means of 10 replicates, while results shown for the clonogenic survival assay 
are means of triplicates, both from a representative experiment. Error bars 
represent the standard deviations. All labeled plots were statistically significantly 
different from the non-irradiated control by Student's t-Test (all p values < 0.001). 
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Figure 2. Luminescent Cell Viability Time Course: Ln18 or T98 cells were 
plated into parallel 96 well plates for each time point (1000 cells per well) and 
incubated for 24 hours prior to radiation exposure. At the indicated time points, 
plates were subjected to the luminescent cell viability assay. Luminescence due 
to cellular ATP content is expressed as RLU; average RLU over time is shown 
for both cell lines (2a, 2c). Labeled plots for each time point indicate a 
statistically significant decrease in cell viability of irradiated cells compared to 
control cells for that particular time point by Student's t-Test (all p values < 
0.001). Percent survival is also shown for both cell lines; the ED50 is most 
effectively obtained 5 days post irradiation in both Ln18 cells irradiated at 5Gy 
(2b), as well as in T98 cells irradiated at 7Gy (2d). Labeled percent survival plots 
indicate a statistically significant difference relative to Day 5 by Student's t-Test 
(all p values < 0.001). Results shown are the means of 10 replicates from a 
representative experiment. Error bars represent the standard deviations. 
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3.2 Confirmation of siRNA efficiency 
Confirmation of WT1 knockdown was achieved through real-time PCR and 
Western Blot. Figure 3 depicts the amount of WT1 mRNA in each of the 
treatment groups 48 hours after siRNA transfection; WT1 mRNA levels were 
normalized to 18s rRNA. There is some non-specific effect observed with 
siscramble in Ln18 cells (Figure 3a), as WT1 mRNA levels are decreased after 
treatment with siscramble; this is not observed in T98 cells (Figure 3b). 
Treatment with siWT1, however, significantly decreases the WT1 mRNA levels in 
both cell lines. In Ln18 cells, the addition of siWTl results in decreases of 84%, 
87%, and 70% in WT1 mRNA levels compared to untreated, Oligofectamine, and 
siscramble controls, respectively. In T98 cells, siRNA against WT1 produces 
decreases of 84%, 84%, and 86% compared to untreated, Oligofectamine, and 
siscramble controls, respectively. Of note, WT1 mRNA levels are significantly 
higher in Ln18 cells, as compared to T98 cells. 
Figures 4 and 5 illustrate WT1 protein expression at various times after 
siRNA transfection in Ln18 and T98 cells, respectively. The doublet consists of 
two WT1 isoforms: WT1 (+I+) at 54kD and WT1 (-I-) at 52kD. At 24 hours after 
transfection, there is decreased WT1 protein expression with treatment of siWT1, 
however residual protein is still observed in both cell lines (Figures 4a and 5a). 
At 48 hours after transfection, there is a marked decrease with minimal residual 
protein in Ln18 cells (Figure 4b), while expression of WT1 is almost absent in 
T98 cells (Figure 5b). At 96 hours after transfection, there is virtually no protein 
expression in both cell lines (Figures 4c and 5c). Densitometry measurements 
(Table 1) reveal a total WT1 protein expression in Ln18 cells at 24 hours after 
siWTl treatment that represents a decrease of 37%, 42%, and 30% relative to 
untreated, Oligofectamine, and siscramble controls, respectively. At 48 hours 
after siWTl treatment, the total WT1 protein expression is decreased 68%, 81 %, 
and 81% respectively, while at 96 hours, siWTl treatment results in greater than 
99.9% decrease in total WT1 protein expression. 
In T98 cells, a decrease in total WT1 protein expression of 72%, 73%, and 
60% relative to the respective controls is observed at 24 hours. At 48 hours, the 
decrease is 99%, 98%, and 98% of the respective controls, while at 96 hours 
expression of WT1 protein is completely absent. In accordance with the real- 
time PCR data, there is evidence of some non-specific effect with treatment of 
siscramble, particularly at 96 hours in Ln18 cells; however, there is a significantly 
greater and marked loss of WT1 protein with siWTl treatment. 
Figure 3. WT1 mRNA Levels: Ln18 (3a) and T98 (3b) cells were treated in 
triplicate and RNA was harvested 48 hours after siRNA transfection. Aliquots of 
the RNA extracts were then subjected to real-time PCR for WT1 mRNA 
quantification. mRNA levels were normalized by dividing the quantity of WT1 by 
that of 18s. The averages of the triplicate values are plotted; error bars represent 
standard deviations. In Ln18 cells, labeled plots indicate a statistically significant 
difference relative to the siWTl treatment group by Tukey's HSD Post Hoc Test 
(all p values < 0.01). In T98 cells, labeled plots also indicate a statistically 
significant difference relative to the siWT1 treatment group by Tukey's HSD Post 
Hoc Test (* indicates p values < 0.01, ** indicates p < 0.05). 
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Figure 4. WT1 Protein Expression in Ln18 Cells at: 24 hours (4a), 48 hours 
(4b), and 96 hours (4c) after siRNA transfection. Cells were plated in 6 well 
plates (250,000 cells per well) and transfected the following day. A total of 6 
wells were transfected for each treatment group to ensure sufficient protein. 
Protein was extracted at indicated times, separated, and transferred to a 
nitrocellulose membrane. Blots were incubated with mouse anti-WT1 
monoclonal antibody diluted 1 :200. An antibody against cyclophilin A (CypA) 
was used to control for protein loading. Densitometric analysis of these results is 
presented in Table 1. 
54kD - 
52kD - WT1 isoforms 
18kD - CYPA 
54kD - 
52kD - WT1 isoforms 
18kD - CYPA 
4 
Figure 5. WT1 Protein Expression in T98 Cells at: 24 hours @a), 48 hours 
(5b), and 96 hours (5c) after siRNA transfection. Cells were plated in 6 well 
plates (250,000 cells per well) and transfected the following day. A total of 6 
wells were transfected for each treatment group to ensure sufficient protein. 
Protein was extracted at indicated times, separated, and transferred to a 
nitrocellulose membrane. Blots were incubated with mouse anti-WT1 
monoclonal antibody diluted 1 :200. An antibody against cyclophilin A (CypA) 
was used to control for protein loading. Densitometric analysis of these results is 
also presented in Table 1. 
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Table 1. Relative Optical Density (ROD) Values: ROD values were obtained 
for Ln18 ( la)  and T98 ( I  b) by densitometry measurements. Normalized values 
were obtained by dividing the WT1 ROD by cyclophilin A (CypA) ROD, while total 
protein values reflect the sum of the normalized 54kD and 52kD values. 
Ln18 cells 
after 24hrs 
Normalized 
54kD [ROD) 
Normalized 
52kD (ROD) 
Normalized 
total WT1 
(ROD) 
Ln18 cells 
after 48hrs 
Normalized 
54kD (ROD) 
Normalized 
52kD (ROD) 
Normalized 
total WT1 
, (ROD) 
Ln18 cells 
after 96hrs 
Normalized 
54kD (ROD) 
Normalized 
52kD (ROD) 
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3.3 Cell Viability and Proliferation 
Ln18 and T98 cells were plated in 6 well plates (250,000 cells per well) 
and transfected the following day with Oligofectamine only, siscramble, or 
siWT1. 24 hours after transfection, cells were harvested and re-plated into 96 
well plates for the luminescent cell viability assay (1 000 cells per well) and 6 well 
plates for the clonogenic cell survival assay (500 cells per well). 48 hours after 
siRNA transfection, cells were irradiated at indicated doses. Figure 6a depicts 
the viability of Ln18 cells after treatment with Oligofectamine only, siscramble, or 
siWT1 in both non-irradiated, con,trol cells and cells irradiated at 5Gy. Statistical 
significance is achieved within both the control group and irradiated groups 
(ANOVA p < 0.0001). There is a statistically significant decrease in Ln18 cell 
viability after treatment with siWTl relative to the untreated group in irradiated 
cells only (p < 0.01). Treatment with siWTl also results in decreased cell viability 
in both control and irradiated cells when compared to Oligofectamine control and 
irradiated cells (p < 0.05 between control cells and p < 0.01 between irradiated 
cells); no significant difference, however, is observed when compared to 
siscramble in either control or irradiated cells. Figure 6b illustrates the percent 
survival of irradiated Ln18 cells relative to control Ln18 cells. Statistical 
significance is again achieved (ANOVA p < 0.0001); treatment with siWT1 
significantly decreases percent survival relative to untreated and Oligofectamine 
treatment groups (both p values < 0.01), although no significant difference in 
percent survival is observed between siscramble and siWT1. 
Figure 7a depicts the viability of T98 cells after identical treatments in both 
control cells and cells irradiated at 7Gy. Statistical significance is achieved within 
both the control and irradiated groups (ANOVA p < 0.0001). Treatment with 
siWTl results in a significant decrease in T98 cell viability relative to all treatment 
groups in both control and irradiated cells (all p values < 0.01). Figure 7b 
illustrates the percent survival of irradiated T98 cells relative to control T98 cells 
for each treatment group. Statistical significance is again achieved (ANOVA p < 
0.0001); treatment with siWTl results in a significant decrease in percent survival 
relative to all treatment groups (all p values < 0.01). 
The ability of cells to reproduce is also an indicator of cell survival. The 
clonogenic cell survival assay measures the ability of cells to proliferate and form 
colonies, and is thus a measure of both cell viability and proliferation. Figure 8a 
illustrates the number of Ln18 colonies formed after treatment in both control and 
irradiated cells; statistical significance is demonstrated within both groups 
(ANOVA p < 0.0001). The number of colonies formed after treatment with siWTl 
is significantly decreased compared to all other treatment groups in both control 
and irradiated cells (all p values < 0.01). Figure 8b illustrates the surviving 
fraction of Ln18 colonies for each treatment group. Statistical significance is also 
achieved (ANOVA p < 0.0001); treatment with siWTl significantly decreases the 
surviving fraction compared to untreated and Oligofectamine, although no 
difference in survival is observed between siscramble and siWT1. No data for 
clonogenic survival in T98 cells are shown because these cells would not grow 
under the conditions of the assay. 
Figure 6. Luminescent Cell Viability of Ln18 Cells: Ln18 cells were treated 
with Oligofectamine, siscramble, or siWTl and irradiated 48 hours after 
transfection. Following a 5-day incubation period, cells were subjected to the 
luminescent cell viability assay. The average of 10 replicates is plotted as 
Average RLU (6a) or as percent survival, comparing irradiated cells of each 
treatment group to its corresponding non-irradiated controls (6b). Error bars 
represent standard deviations. Both graphs are representative of 3 separate, 
independent experiments. Plots labeled with a * reflect p values < 0.01 when 
compared to each other, while plots labeled with a ** reflect a p value < 0.05 
relative to each other by Tukey's HSD Post Hoc Test. Other comparisons were 
statistically significant but are not shown for purposes of clarity. 
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Figure 7. Luminescent Cell Viability of T98 Cells: T98 cells were treated with 
Oligofectamine, siScram ble, or siWTl and irradiated 48 hours after transfection. 
Following a 5-day incubation period, cells were subjected to the luminescent cell 
viability assay. The average of 10 replicates is plotted as Average RLU (7a) or 
as percent survival, comparing irradiated cells of each treatment group to its 
corresponding non-irradiated controls (7b). Error bars represent standard 
deviations. Both graphs are representative of 3 separate, independent 
experiments. Plots labeled with * are statistically different from each other, plots 
labeled with ** are statistically different from each other, plots labeled with $ are 
statistically different from each other, and plots labeled with $$ are statistically 
different from each other. All p values are < 0.01 by Tukey's HSD Post Hoc Test. 
Other statistical differences are not shown for purposes of clarity. 
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Figure 8. Clonogenic Cell Survival of Ln18 Cells: Ln18 cells were treated with 
Oligofectamine, siscramble, or siWTl and irradiated 48 hours after transfection. 
8 days after radiation exposure, cells were analyzed for clonogenic survival. The 
number of colonies is either plotted as the average of nine replicates (8a) or as a 
surviving fraction relative to non-irradiated controls (8b). Error bars represent 
standard deviations. Both graphs represent the combination of 3 separate, 
independent experiments. Plots labeled with * are statistically different from each 
other, plots labeled with ** are statistically different from each other, plots labeled 
with $ are statistically different from each other, and plots labeled with $$ are 
statistically different from each other. All p values are < 0.01 by Tukey's HSD 
Post Hoc Test. Other statistical differences are not shown for purposes of clarity. 
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CHAPTER 4 
DISCUSSION 
To date, there are no known papers that have investigated a role for WT? 
in the radiation sensitivity of glioblastoma cells or any other cell type. Studies 
have shown, however, that WT1 is expressed in the majority of high grade 
gliomas79-B' and not in normal glial cells8'. While previous studies demonstrate 
that WTl's target genes do function to confer radiation resistance in glioblastoma 
CellS14-16;20;43;83 
, there can only be speculation that WT1 may also be responsible 
for the observed resistance. After characterizing the effects of gamma-induced 
irradiation on two glioblastoma cell lines expressing WT1 and confirming siRNA 
efficiency, we determined that WT1 functions to both promote cell proliferation as 
well as to aid glioblastoma cells in evading irradiation-induced death. 
There are two ways of interpreting the data presented, depending on what 
is considered the appropriate control for siRNA treatment. The use of siRNAs to 
silence target genes is a relatively recent advancement made in molecular 
biology. As exciting and extremely useful as this tool is, the lack of valuable 
controls is a current topic of debate. The two major controls used in these 
experiments were Oligofectamine as a vehicle control and the pool of non- 
targeting siRNAs (with Oligofectamine) purchased from Dharmacon. While the 
scrambled siRNAs seem like the more useful control, members of the 2003 
Horizon meeting on RNA expressed concern that these siRNAs are often too 
unrelated to the target gene to be a truly informative controlB4. Furthermore, 
there is apparently a fine line between siRNAs and miRNAs (micro RNAs). Like 
siRNAs, miRNAs also inhibit translation through a pathway closely related to 
S ~ R N A S ~ ~ .  Consequently, while these siRNAs are designed to be non-targeting, 
they may in fact affect the levels of the target gene or other genes through an 
miRNA-like mechanism. These unanticipated effects may thus cause this control 
to be of limited value. With this in mind, let us now turn to the data presented. 
If siscramble is used as the control, the Ln18 ATP data suggest that WT1 
has no effect on the radiation sensitivity of these cells, as no significant 
difference is seen between the two treatment groups. The Ln18 clonogenic data, 
however, does implicate a small but significant role for WTI. The data 
demonstrate that silencing WT1 increases the radiation sensitivity of Ln18 cells, 
although no difference in cell survival is observed; this suggests that WT1 
promotes cell survival, but that the effect of silencing WT1 only adds to the 
effects of irradiation, rather than enhancing this mode of destruction. The 
contradictory results between the ATP data and the clonogenic data may be the 
result of two different endpoints. While the ATP assay reflects the number of 
metabolically active cells, the clonogenic cell survival assay reflects only the 
number of cells with reproductive capacity; thus the resulting survival after 
treatment with siWTl is higher using the ATP assay compared to the clonogenic 
assay. In evaluating the two sets of data, perhaps what is most clinically relevant 
in glioblastoma is the loss of reproductive capacity; since neurological deficits 
and ultimate death are the result of tumor cells proliferating and invading 
surrounding normal tissue, inhibition of growth is the more ideal outcome. 
If however, Oligofectamine is considered the control in these experiments, 
WT1 plays more than a minor role in protecting Ln18 cells from irradiation; in 
fact, silencing WT1 considerably enhances the effects of irradiation in these cells, 
as significant differences are observed in cell viability, clonogenic capacity, and 
percent survival. An argument can be made that Oligofectamine is perhaps the 
more valuable control in this cell line, since the levels of WT1 are altered by 
treatment with siScramble, as seen with both real-time PCR and Western blot 
data. While treatment with siWTl produces a greater deficit, decreases in the 
WT1 levels with addition of the scrambled siRNAs may contribute to the cytotoxic 
effects observed. 
The role of WT1 in radiation sensitivity is further confirmed in experiments 
with T98 cells; silencing WT1 in these cells enhances their radiation sensitivity, 
as significant differences in both cell viability and percent survival are seen with 
treatment of siWT1, regardless of the control used. The effect, however, is more 
pronounced when Oligofectamine is considered the control. In addition, while 
very minimal decreases of WT1 protein levels are observed with siscramble in 
Western blot analysis, it does not seem to have significant cytotoxic effects. 
Unfortunately, clonogenic survival could not be assessed with T98 cells due to 
poor colony formation by untreated control cells; however, because the Ln18 
data suggest that the clonogenic cell survival assay may be a more sensitive 
test, it does not seem likely that conclusions drawn from the T98 data presented 
would be significantly affected. One way to confirm this would be to consider an 
alternative test such as the colony formation in soft agar assay. Although normal 
cells undergo anchorage-dependent growth, T98 cells have undergone malignant 
transformation, which may permit them to grow in the semi-solid media and allow 
for parallel clonogenic testing. These data would be valuable to further confirm 
that treatment with siWTl enhances the radiation sensitivity of T98 cells. 
While we have shown that silencing WT1 does enhance radiation 
sensitivity, the magnitude of its effects is short of remarkable; this may be due to 
the time chosen to irradiate the cells. While there is significant knockdown at 48 
hours after siRNA transfection in both cell lines, WT1 protein deficits are most 
pronounced at 96 hours after transfection; there is very minimal residual WT1 
protein in Ln18 cells and a complete lack of WT1 protein in T98 cells at 96 hours. 
In these experiments, cells were irradiated at 48 hours after transfection to 
minimize the amount of stress induced. Cells were transfected in 6 well plates 
because verification of knockdown was not possible in the 96 well plates required 
for the luminescent ATP assay. Thus re-plating was necessary and performed 
24 hours after siRNA transfection; cells were irradiated 24 hours later to allow for 
recovery from re-plating stresses. Perhaps it would be of value to investigate 
multiple time points to perform the irradiation; since protein levels are lowest at 
96 hours, irradiating the cells at this time point may produce a more striking 
effect. Of interest, while untreated Ln18 cells express significantly more WT1 
than untreated T98 cells, Ln18 cells contain almost five times more WTl  mRNA 
levels (relative to 18s RNA) than T98 cells, even after treatment with siWT1. 
This may account for the more marked effect seen in the T98 experiments. 
In regards to the different controls used, it seems that each cell line should 
utilize a different control. Significant reductions in WT1 levels are observed in 
Ln18 cells treated with siscramble. While treatment with siWTl results in a 
greater deficit, WTl mRNA levels are reduced to half the amount expressed in 
untreated cells after treatment with siscramble. This suggests that siscramble 
may be working through other mechanisms, possibly through an miRNA-like 
mechanism to inhibit translation of WTI. Evidence of this is also observed in 
Western blot analysis, particularly at the 96 hour time point. This may contribute 
to the lack of statistical differences observed between the siscramble and siWTl 
treatment groups. While the possibility of off-target effects cannot be entirely 
excluded, it does not appear to be a likely event since no statistical differences in 
cell viability are observed between non-irradiated cells treated with siscramble 
and siWT1. Therefore, Oligofectamine appears to be the more appropriate 
control in Ln18 cells since WT1 levels are not significantly altered. 
Alternative controls for future studies with Ln18 cells may include just one 
non-targeting siRNA, rather than the pool of four used in these experiments; this 
could minimize effects on WT1 levels. Additionally, siCONTROL RISC-free 
siRNA (Dharmacon) has been developed to impair uptake and processing by the 
RNA-induced silencing complex (RISC), which is the mechanism by which 
siRNAs target mRNAs for degradation; this may also be a valuable control, 
although both alternatives mentioned should be validated before use. In contrast 
to Ln18 cells, siscramble does not significantly alter WT1 mRNA or protein levels 
in T98 cells; thus, siscramble is the more appropriate control for these cells. 
While cellular context may account for the differences in controls between these 
two cell lines, it is probably best to determine an appropriate control that can be 
used in both cell lines. 
Overall, our findings that silencing WT1 does enhance radiation sensitivity 
are not surprising, given that WTl has also been linked to chemotherapy 
resistance; 'this has been reported in the literature as well as in studies done by 
members of our laboratory. These two therapies work through similar 
mechanisms, in that they both induce DNA damage. Both WT1 and the 
multidrug resistance 1 (MDRI) gene products were detected in patients with 
acute myeloid leukemia; moreover, high levels of WT1 were significantly 
associated with high levels of MDRI~~.  Consistent with these findings, 
correlation between upregulation of WT1 and MDRI -mediated vincristine 
resistance in leukemiallymphoma cells lines has also been reported85. In 
addition, transcriptional activation of the Bcl-2 promoter by WT1 has been 
associated with resistance to three chemotherapy agentsG8, as previously 
described. While WT1 has been implicated in chemoresistance, no studies have 
reported this function in gliomas. 
WT1 has also been correlated with other features that contribute to the 
malignancy of glioblastomas. One such characteristic is the ability of GBM cells 
to invade surrounding normal brain tissue. A recent study demonstrated that 
constitutive expression of the WT1 (-I-) isoform was associated with enhanced 
cell migration and invasion in vitro using ovarian cancer cells86. This novel study 
indicated that WT1 regulates cytoskeletal components to achieve these 
oncogenic functions. Invasion, however, is not limited to high grade gliomas; 
low-grade gliomas are also capable of invading surround normal brain. 
Additionally, since WT1 correlates more strongly with high grade gliomas, this 
raises questions as to whether WT1 plays a significant role in the invasion of 
glioblastomas. Another malignant trait of GBM is genomic instability. Because 
WT1 has been shown to inhibit apoptosis by suppression of p53 as well as by 
activation of Bcl-2, it is possible that WT1 promotes genomic instability in 
glioblastomas by preventing cellular suicide in cells that have sustained 
significant DNA damage. These functions, however, have yet to be validated in 
GBMs. 
Future Directions: With regards to radiation resistance, it would be 
valuable to examine whether different time points after radiation exposure would 
provide more pronounced effects. Furthermore, a single irradiation dose based 
on the ED50 was chosen for these experiments. The rationale behind using the 
ED50 was to utilize a dose that would have obvious effects in order to determine 
whether treatment with siWTl would alter the radiation sensitivity of these cell 
lines. Either too low or too high of a dose would make detection of any effects 
rather difficult. It may be of interest for future studies to investigate the effects of 
using a slightly higher dose with multiple radiation exposures, as is done clinically 
with fractionated doses. It is possible that the effects of silencing WT1 may show 
a greater effect using this approach and would be more relevant to patient care if 
proven. In addition, experiments that utilize siRNAs to silence genes should first 
identify a control that does not significantly alter levels of the target gene. To 
better understand the function of WT1 in glioblastoma, future studies should 
address the effects of WT1 on its known target genes, specifically in GBMs. 
Additional investigation could validate WT1 activation/upregulation of the 
previously discussed pro-survival genes (ie EGFR, PDGFR, Bcl-2) or the 
suppression of apoptotic genes like p53 in glioblastomas; this would further 
elucidate its probable function as an oncogene in this cell type. 
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